Core Viewpoint - Jiangyin Pharmaceutical is seeking to go public on the Hong Kong Stock Exchange, but the China Securities Regulatory Commission (CSRC) has requested additional compliance information regarding its offshore structure and reverse mergers [1][2]. Group 1: Regulatory Compliance - The CSRC has asked Jiangyin Pharmaceutical to provide detailed explanations regarding the compliance of its offshore structure and reverse investment, including adherence to foreign exchange management, overseas investment, foreign investment, and tax management regulations [2]. - The company must clarify the legality of its domestic operating entity established in Shanghai and its historical equity changes [2]. Group 2: Financial Data and Business Operations - Jiangyin Pharmaceutical is required to disclose the proportion of its financial statements that is attributed to its domestic operating entity, and whether unpaid registered capital could negatively impact its business operations and debt repayment capabilities [2]. - The company must provide a conclusive opinion on whether its business scope and actual operations involve sectors that are restricted or prohibited for foreign investment [2]. Group 3: Company Overview - Jiangyin Pharmaceutical is a global clinical-stage biotechnology company focused on maximizing the clinical and commercial value of siRNA therapies [2]. - The company aims to innovate the current treatment standards for chronic diseases through the development of first-in-class and best-in-class siRNA therapies, supported by a proprietary siRNA technology platform and a global collaboration network [2].
新股消息 | 靖因药业拟港股上市 中国证监会要求补充说明搭建离岸架构及返程并购的合规性等
Zhi Tong Cai Jing·2026-01-05 13:08